SGD Pharma, a global market leader in pharmaceutical glass primary packaging solutions, has released its 2025 Sustainability Report detailing significant progress in its sustainable development journey and reinforcing its position at the forefront of environmental, social and ethical performance in the global glass manufacturing industry.
SGD Pharma has achieved the top-grade Platinum EcoVadis rating with a score of 90/100, placing it among the top 1 percent of all companies for the second time in a row. Alongside parallel CDP Climate A rating, CDP Supplier Engagement A score and CDP Water score of B, these recognitions highlight SGD Pharma’s commitment to embedding sustainability at the core of its strategy and operations, passing the gains to the pharma customer supply chain.
SGD Pharma continues to lead the decarbonisation of the pharmaceutical glass sector and deliver tangible progress towards its climate goals, achieving a 27% reduction in Scope 1 and Scope 2 greenhouse gas (GHG) emissions in 2025 compared with its 2022 baseline. This performance is supported by major investments in industrial transformation, including the electrification of production processes, the adoption of renewable electricity and the phasing out of heavy fuel oil across its manufacturing sites. The company is confident to achieve its Science Based Targets initiative (SBTi) commitments, following a 1.5 degrees Celsius trajectory, with ambitious goals to reduce GHG emissions by 42 percent by 2030.
Other key progress includes:
- Becoming the first glass manufacturer in China to achieve ISO 14021 certification for post-consumer recycled content at its Zhanjiang site
- Improved water efficiency, with reduced withdrawal per tonne produced
- Biodiversity initiatives (16,568 mangroves planted with partners in China since 2022)
- Continued certification to ISO 45001 across manufacturing sites
- A global whistleblowing training programme
Olivier Rousseau, CEO of SGD Pharma, commented, “Building a responsible value chain is essential to achieving meaningful, long-term impact. By working closely with our suppliers and raising expectations across the board, we are creating shared value while accelerating the transition to more sustainable healthcare packaging.”
“While we celebrate these achievements, we remain focused on the challenges and opportunities ahead,” he added. “Our ambition is to continue raising the bar, building a more resilient, responsible company that creates long-term value for patients, customers, partners and society.”